Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment.

Abstract

Pyroptosis induced by the N-terminal gasdermin domain (GSDM^NT) holds great potential for anti-tumor therapy. However, due to the extreme cytoxicity of GSDM^NT, it is challenging to efficiently produce and deliver GSDM^NT into tumor cells. Here, we report the development of two strategies to package recombinant adeno-associated virus (rAAV) expressing GSDM^NT: 1) drive the expression of GSDM^NT by a mammal specific promoter and package the virus in Sf9 insect cells to avoid its expression; 2) co-infect rAAV-Cre to revert and express the double-floxed inverted GSDM^NT. We demonstrate that these rAAVs can induce pyroptosis and prolong survival in preclinical cancer models. The oncolytic-viruses induce pyroptosis and evoke a robust immune-response. In a glioblastoma model, rAAVs temporarily open the blood-brain barrier and recruit tumor infiltrating lymphocytes into the brain. The oncolytic effect is further improved in combination with anti-PD-L1. Together, our strategies efficiently produce and deliver GSDM^NT into tumor cells and successfully induce pyroptosis, which can be exploited for anti-tumor therapy.